Company · Public · ISM
Insilico Medicine
Generative chemistry and target discovery company with clinical assets originating from its AI platform.
EvidenceModeratePhase 2a readout
Listing
Public
Ticker
ISM
Headquarters
Hong Kong / Boston
Founded
2014
Technology
Generative AI drug discovery
Category
Market cap
$1.3B
Longevity thesis
If AI-originated molecules read out positively in humans, discovery cost per aging-related target falls materially.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| Rentosertib | Phase 2 | Idiopathic pulmonary fibrosis |
| Aging target portfolio | Discovery | Fibrosis and senescence |
Recent developments
- 4 Aug 2026Published Phase 2a results for an AI-originated fibrosis candidate.
Scientific evidence
EvidenceModerate
Human Phase 2a data, small sample.
LONGEFI analysis
The most direct public proxy for AI-originated drug discovery reaching clinical relevance in aging-adjacent indications.
Analysis is research commentary. It is not investment advice or a recommendation.